Trending News
News
News
Structural Bio Paired With Computational Design To Create Anticancer Agent
Researchers have used computational design to combine the structures of three molecular fragments into a single chemical compound that was able to dock in a binding pocket on tubulin and disable it. This caused disruption to the cytoskeletal structure of cancer cells, leading to cell death.
News
Epigenetic Regulator Plays a Role in Drug Resistance in Some Lung Cancer Patients
A research team has discovered that epigenetic-modifying proteins contribute to drug resistance in some cases of non-small cell lung cancer.
News
Single Dose of HPV Vaccine Highly Effective
A new study has shown that a single dose of the HPV vaccine has the same efficacy as the current three-dose regimen.
News
Lung Cancer Drug Improves Survival Rates for Bladder Cancer Patients in Phase 2 Trial
Researchers have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.
News
Drug Screen Identifies Promising Compounds To Treat Bladder Cancer
A chemical compound screen was performed on cell cultures representing different stages and subtypes of bladder cancer revealing several promising candidates with inhibitory effects.
News
Immune System Attacks Itself in a Rare Type of Blood Cancer
An international study has shown that the body’s immune system attacks itself in a rare type of blood cancer called large granular lymphocyte (LGL) leukemia. Therefore, treatment strategies should be targeted at the immune system as well as the cancer cells themselves.
News
Virally-Programmed Extracellular Vesicles Designed To Shrink Tumors
A research team has designed a virus that selectively infects cancer cells and causes the infected cells to release RNA-containing extracellular vesicles that blunt the antiviral response of surrounding cancer cells.
News
Lung Cancer Patients With Variant of the CTLA-4 Gene May Respond Better to Immunotherapy
A variant of the CTLA-4 gene was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in other lung cancer patients and healthy individuals.
News
Therapy That "Tricks" Cancer Cells Is Set To Begin Clinical Testing in Glioblastoma Patients
The discovery that gallium maltolate has anticancer activity against glioblastoma in preclinical studies opens the door for developing it as a drug for the treatment of glioblastoma.
News
Two Drugs Targeting DNA Damage Response Show Promise in Early-Stage Cancer Trials
Early-stage clinical trials of two drugs that target the DNA damage response pathway in cancers have shown that the drugs are safe and clinically beneficial for treating advanced tumors.
Advertisement